mercredi 22 janvier 2020

Onco Actu du 22 janvier 2020


1.4 BIOLOGIE - TECHNOS, MODÈLES



Technologies to watch in 2020 [Nature]











2.6 ETIOLOGIE - ENVIRONNEMENT



SlimeGate 2/7: Predatorts 3.2/4: The Predatort Victim Exchange [The Risk-Monger]











3.1.1 PRÉVENTION - TABAC - E-CIGS



JUUL use more than doubled among U.S. teens, young adults in one year [Reuters]











3.3 PRÉVENTION - VACCINS



JPM: Merck turns to contract manufacturers to help with Gardasil supply; plans 2023 plant openings [Fierce Pharma]











HPV vaccine almost eradicates risk of cervical cancer in young women, analysis suggests [King's College London]










Doubts raised about effectiveness of HPV vaccines [Newcastle University]










HPV infections nearly eliminated in England under vaccine scheme [The Guardian]











3.5 PRÉVENTION - UV



Sunscreen ingredients really do seep into the blood. Is that bad? [Reuters]











Are Sunscreens Safe? FDA Studies Suggest Its Time We Get Answers [Dr. Len]










4.12 BIOPSIES LIQUIDES



FNIH Team Selects Cancer Biomarkers in Phase I of Liquid Biopsy Reference Standards Project [Genome Web]











4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS



Myriad Submits sPMA for BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Metastatic Castration-resistant Prostate Cancer [Myriad]











4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS



Cervical cancer cases soaring among women in their late 20s [The Telegraph]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Scientists Reveal How Lung Cancer Cancer Cells Avoid Death from Targeted Drugs [Dana-Farber Cancer Institute]











Changes in Metabolism Help Melanomas Spread [NCI]











Scientists find unexpected anti-cancer activity in range of non-oncology drugs — study [EndPoints]











Editing cancer-causing RNA delivers precision strike on triple-negative breast cancer [Scripps Research]











5.10 TRAITEMENTS - ESSAIS



Targeted Therapy Combination Shows Promising Antitumor Activity in Aggressive Meningiomas [AACR]











What do Mass General, the NCI and Mayo Clinic have in common? They routinely blow off an FDA rule on posting trial results [EndPoints]










Select few cancer patients enroll in potentially life-extending clinical trials [Penn State]










Adding chemotherapy to radiotherapy for bladder cancer shows benefits for patients [Institute of Cancer Research]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Side Effect of CAR T Therapy Caused by Pyroptosis: Mouse Study [The Scientist]











Deciphering a cancer treatment’s dark side [Science]










5.12.5 IMMUNOTHÉRAPIES - PHARMA



BeiGene cancer drug data sets up China duel with Merck [Biopharma Dive]











BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis [BeiGene]











BeiGene lines up its first shot at cracking the megablockbuster PD-1 market for lung cancer. But can they overcome underdog status? [EndPoints]











5.2 PHARMA



FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in HRR-Mutated Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review [Merck]











AstraZeneca nabs priority review for Lynparza in prostate as PARP inhibitors expand to more cancers [EndPoints]











AstraZeneca plans to spend $535M-plus to expand its R&D network and manufacturing ops in France [EndPoints]











5.2.5 PHARMA - GSK



US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma [GSK]











GSK’s ‘breakthrough’ BCMA cancer drug gets a priority review — and a big win for the oncology R&D team [EndPoints]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



Genmab Announces European Marketing Authorization for DARZALEX® (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma [Genmab]











5.5.5 ASCO (GASTRO-INTESTINAL)



Bayer to showcase new data including research in immuno-oncology at ASCO GI Cancers Symposium 2020 [Bayer]











Blood-Based Test Could Help Identify Hard-to-Detect Gastrointestinal Cancers [ASCO]











New Drug Combinations Maintain Quality of Life for Patients With Colorectal and Liver Cancers [ASCO]











Gut Bacteria May Be One Culprit for Increase of Colorectal Cancer in Younger People [Georgetown University]











6. LUTTE CONTRE LES CANCERS



Our best weapons against cancer are not magic bullets [Nature]